nAbs and anti-S IgG against VoC
In the ChAdOx1 nCoV-19 prime cohort at day 29, SII-NVX-CoV2373 booster induced 3.5 fold-rise (95% CI 2.3, 5.3) in GMTs and 84% (95% CI 63.92, 95.46) seroresponse rate for nAbs against Omicron B.1.1.529 (BA.1), while a 1.3 fold-rise (95% CI 1.0, 1.7) in GMTs and 40% (95% CI 21.13, 61.33) seroresponse rate was seen with the ChAdOx1 nCoV-19 booster (Fig. Summary of Neutralizing Antibodies (nAb) against Omicron B.1.1.529 at each visit (Per protocol population). GMT: Geometric Mean Titer. For each study vaccine, the GMT of Neutralizing Antibodies (nAb) and 95% CI were calculated by transforming to the original scale of logIn the BBV152 prime cohort at day 29, SII-NVX-CoV2373 booster induced 3.8 fold-rise (95% CI 2.3, 6.3) in GMTs and 72% (95% CI 50.61, 87.93) seroresponse rate for nAbs against Omicron B.1.1.529 while there was no rise in GMTs and only 24% (95% CI 9.36, 45.13) seroresponse rate with BBV152 booster (Fig. In the ChAdOx1 nCoV-19 prime cohort at day 29, SII-NVX-CoV2373 booster induced 3.9 fold-rise (95% CI 2.7, 5.6) in GMEUs and 73.91% (95% CI 51.59, 89.77) seroresponse rate for anti-S IgG against Omicron BA.1 and 4.1 fold-rise (95% CI 2.9, 5.7) in GMEUs and 86.96% (95% CI 66.41, 97.22) seroresponse rate against Omicron BA.5. ChAdOx1 nCoV-19 booster induced 2.1 fold-rise (95% CI 1.4, 3.0) in GMEUs and 43.48% (95% CI 23.19, 65.51) seroresponse rate for anti-S IgG against Omicron BA.1 and 2.4 fold-rise (95% CI 1.7, 3.3) in GMEUs and 47.83% (95% CI 26.82, 69.41) seroresponse rate against Omicron BA.5. (Fig. Summary of Anti-S IgG against Omicron BA.1 and Omicron BA.5 at each visit (Per protocol population). In the BBV152 prime cohort at day 29, SII-NVX-CoV2373 booster induced 8.3 fold-rise (95% CI 5.1, 13.3) in GMEUs and 91.3% (95% CI 71.96, 98.93) seroresponse rate for anti-S IgG against Omicron BA.1 and 9.6 fold-rise (95% CI 5.9, 15.8) in GMEUs and 95.65% (95% CI 78.05, 99.89) seroresponse rate against Omicron BA.5; while there was no rise in GMEUs and 4.35% (95% CI 0.11, 21.95) seroresponse rate against Omicron BA.1 and BA.5 seen with BBV152 booster (Fig. 